Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CV-04
- Development stage
- Preclinical
- Lead developer
- Cureverse
- Modality
- Small Molecules
01
Overview
CV-04 is a small molecule modulator of the Peroxisome Proliferator-Activated Receptor delta (PPARδ), currently in the hit-to-lead stage of development by Cureverse. PPARδ is a nuclear receptor that plays a pivotal role in regulating fatty acid metabolism, glucose utilization, and inflammatory signaling. CV-04 is being developed for the treatment of metabolic diseases, including diabetes, and various inflammatory conditions. As a PPARδ modulator, it is designed to influence gene expression patterns that improve metabolic health and reduce systemic inflammation. The program is currently in the early preclinical stages of optimization.
- Other names
- PPARδ asset
02
Targets
PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on CV-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CV-04.